Product/Composition:- | Bortezomib |
---|---|
Strength:- | 1 mg/vial, 3.5 mg/vial |
Form:- | Injection (lyophilized powder for solution) |
Reference Brands:- | Velcade® (US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Bortezomib Injection is a proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma, available in 1 mg and 3.5 mg vials in the US and EU.
Bortezomib Injection, available in 1 mg and 3.5 mg lyophilized vials, is a leading oncology drug used for multiple myeloma and mantle cell lymphoma in the EU and US markets. As a proteasome inhibitor, Bortezomib disrupts protein degradation in cancer cells, inducing apoptosis and inhibiting tumor growth. Marketed under the brand Velcade®, this essential anticancer agent is available for IV and subcutaneous use. GMP-compliant manufacturers supply Bortezomib as a sterile injectable formulation, making it a high-demand product for pharmaceutical B2B sourcing, licensing, and global distribution in regulated markets.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications